50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
How High Can Copper Go? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
How High Can Copper Go? (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
How High Can Copper Go? (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
How High Can Copper Go? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
How High Can Copper Go? (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
How High Can Copper Go? (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
How High Can Copper Go? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
How High Can Copper Go? (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
How High Can Copper Go? (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
How High Can Copper Go? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
How High Can Copper Go? (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
How High Can Copper Go? (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
NASDAQ:SILK

Silk Road Medical - SILK Stock Forecast, Price & News

$41.67
+1.63 (+4.07%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$39.91
$42.15
50-Day Range
$38.79
$49.20
52-Week Range
$27.21
$63.22
Volume
233,290 shs
Average Volume
271,059 shs
Market Capitalization
$1.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33

Silk Road Medical MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
18.4% Upside
$49.33 Price Target
Short Interest
Bearish
6.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$5.35 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.81) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

983rd out of 1,069 stocks

Surgical & Medical Instruments Industry

97th out of 104 stocks

SILK stock logo

About Silk Road Medical (NASDAQ:SILK) Stock

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Receive SILK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silk Road Medical and its competitors with MarketBeat's FREE daily newsletter.

SILK Stock News Headlines

Is the US Military Secretly Under Chinese Control?
Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...
SILK Crosses Above Average Analyst Target
Earnings Preview: Silk Road Medical
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
Analyst Ratings for Silk Road Medical
See More Headlines
Receive SILK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silk Road Medical and its competitors with MarketBeat's FREE daily newsletter.

SILK Company Calendar

Last Earnings
11/09/2021
Today
9/27/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SILK
Employees
352
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.33
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-49,810,000.00
Pretax Margin
-53.13%

Debt

Sales & Book Value

Annual Sales
$101.47 million
Book Value
$2.27 per share

Miscellaneous

Free Float
32,541,000
Market Cap
$1.47 billion
Optionable
Not Optionable
Beta
1.50

Key Executives

  • Ms. Erica J. RogersMs. Erica J. Rogers (Age 58)
    Pres, CEO & Director
    Comp: $987.28k
  • Mr. Lucas W. BuchananMr. Lucas W. Buchanan (Age 45)
    CFO & COO
    Comp: $790.27k
  • Mr. Andrew S. DavisMr. Andrew S. Davis (Age 53)
    Chief Commercial Officer
    Comp: $777.22k
  • Mr. Richard M. RuedyMr. Richard M. Ruedy (Age 55)
    Exec. VP of Clinical, Regulatory Affairs & Quality Assurance
    Comp: $449.68k
  • Ms. Mhairi L. Jones
    VP of Fin. & Accounting
  • Mr. Matthew McCarthy
    VP of Marketing
  • Ms. Alison Highlander
    VP of HR
  • Dr. Sumaira MacDonald
    Exec. Medical Director
  • Dr. William Whealon Ph.D.
    Exec. VP of R&D
  • Lynn Lewis
    Investors Relations Officer













SILK Stock - Frequently Asked Questions

Should I buy or sell Silk Road Medical stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings
or view top-rated stocks.

What is Silk Road Medical's stock price forecast for 2022?

5 analysts have issued twelve-month price targets for Silk Road Medical's stock. Their SILK share price forecasts range from $33.00 to $66.00. On average, they expect the company's share price to reach $49.33 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for SILK
or view top-rated stocks among Wall Street analysts.

How have SILK shares performed in 2022?

Silk Road Medical's stock was trading at $42.61 at the start of the year. Since then, SILK shares have decreased by 2.2% and is now trading at $41.67.
View the best growth stocks for 2022 here
.

When is Silk Road Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SILK earnings forecast
.

How were Silk Road Medical's earnings last quarter?

Silk Road Medical, Inc (NASDAQ:SILK) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The firm had revenue of $24.70 million for the quarter, compared to the consensus estimate of $26.03 million. Silk Road Medical had a negative net margin of 53.13% and a negative trailing twelve-month return on equity of 82.20%. During the same period in the prior year, the business posted ($0.31) EPS.

What guidance has Silk Road Medical issued on next quarter's earnings?

Silk Road Medical updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $128.00 million-$133.00 million, compared to the consensus revenue estimate of $129.32 million.

What other stocks do shareholders of Silk Road Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

When did Silk Road Medical IPO?

(SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

What is Silk Road Medical's stock symbol?

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Who are Silk Road Medical's major shareholders?

Silk Road Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Deerfield Management Company L.P. Series C (7.60%), Clearbridge Investments LLC (4.37%), Kayne Anderson Rudnick Investment Management LLC (3.84%), TimesSquare Capital Management LLC (2.43%), State Street Corp (2.34%) and Ensign Peak Advisors Inc (1.35%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Pincus & Co Warburg and Richard Ruedy.
View institutional ownership trends
.

How do I buy shares of Silk Road Medical?

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silk Road Medical's stock price today?

One share of SILK stock can currently be purchased for approximately $41.67.

How much money does Silk Road Medical make?

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $1.47 billion and generates $101.47 million in revenue each year. The company earns $-49,810,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does Silk Road Medical have?

The company employs 352 workers across the globe.

How can I contact Silk Road Medical?

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for the company is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at investors@silkroadmed.com, or via fax at 408-720-9013.

This page (NASDAQ:SILK) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.